Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company’s NanoPortal platform technology, under development for chronic weight management. Vivani designed NanoPortal technology to steadily deliver medication over extended periods of time. The company aims to guarantee correct doses for patients while […]
Clinical Trials
Trinity Biotech reports positive clinical findings for next-gen CGM
Trinity Biotech (Nasdaq:TRIB) today announced new clinical findings supporting its next-generation continuous glucose monitor (CGM). Dublin, Ireland-based Trinity unveiled the CGM+ next-gen wearable biosensor in July 2025. With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages of device development. The new […]
Terrestrial Bio doses first patients in GLP-1 patch trial
Terrestrial Bio announced today that it dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic semaglutide. Boston-based Terrestrial (formerly Vaxess Technologies) is evaluating VX-201, a needle-free microarray patch (MAP) in the trial. The company designed its MAP technology features a soluble microarray with tips that gradually dissolve into […]
Airiver treats first patient in drug-coated balloon study for chronic rhinosinusitis
Airiver Medical today announced the successful treatment of the first patient in a pivotal clinical trial of its drug-coated balloon (DCB). The first patient received treatment for chronic rhinosinusitis (CRS) in its RESTORE-2 U.S. pivotal clinical trial. It evaluates the Brooklyn Park, Minnesota-based company’s Airiver ESSpand sinus DCB. Dr. Andrew Gould treated the first patient […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Beta Bionics real-world data shows 25% time in range improvement with iLet
Beta Bionics (Nasdaq:BBNX) said real-world data discussed last weekend highlighted the impact of its iLet Bionic Pancreas platform. The company said conversations with clinicians at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans covered improved outcomes and easier follow-up visits. The Irvine, California-based company said outcomes demonstrated how iLet supports diabetes care […]
Biolinq data backs autonomous, needle-free CGM
Biolinq today shared new clinical findings supporting the use of its autonomous, needle-free continuous glucose monitor (CGM). San Diego-based Biolinq develops the Shine sensor, which integrates glucose, activity and sleep information into a single device with autonomous operation. The first-of-its-kind system utilizes a patch on the forearm to provide real-time glucose feedback through a primary […]
Terrestrial Bio data backs needle-free patch for GLP-1 delivery
Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies. Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery […]
Adaptyx study backs wearable multi-analyte sensor
Adaptyx Biosciences today announced clinical findings supporting its wearable sensor for continuous, multi-day free cortisol measurement. Menlo Park, California-based Adaptyx, a Stanford University spinout, shared the first data for its sensor at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. The studies looked at the sensor measuring free cortisol from dermal interstitial […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
